Androgen Excess in Women

Experience with over 1000 Consecutive Patients

Ricardo Azziz, L. A. Sanchez, E. S. Knochenhauer, C. Moran, J. Lazenby, K. C. Stephens, K. Taylor, L. R. Boots

Research output: Contribution to journalReview article

484 Citations (Scopus)

Abstract

The objective of the present study was to estimate the prevalence of the different pathological conditions causing clinically evident androgen excess and to document the degree of long-term success of suppressive and/or antiandrogen hormonal therapy in a large consecutive population of patients. All patients presenting for evaluation of symptoms potentially related to androgen excess between October 1987 and June 2002 were evaluated, and the data were maintained prospectively in a computerized database. For the assessment of therapeutic response, a retrospective review of the medical chart was performed, after the exclusion of those patients seeking fertility therapy only, or with inadequate follow-up or poor compliance. A total of 1281 consecutive patients were seen during the study period. Excluded from analysis were 408 patients in whom we were unable to evaluate hormonal status, determine ovulatory status, or find any evidence of androgen excess. In the remaining population of 873 patients, the unbiased prevalence of androgen-secreting neoplasms was 0.2%, 21-hydroxylase-deficient classic adrenal hyperplasia (CAH) was 0.6%, 21-hydroxylase-deficient nonclassic adrenal hyperplasia (NCAH) was 1.6%, hyperandrogenic insulin-resistant acanthosis nigricans (HAIRAN) syndrome was 3.1%, idiopathic hirsutism was 4.7%, and polycystic ovary syndrome (PCOS) was 82.0%. Fifty-nine (6.75%) patients had elevated androgen levels and hirsutism but normal ovulation. A total of 257 patients were included in the assessment of the response to hormonal therapy. The mean duration of follow-up was 33.5 months (range, 6-155). Hirsutism improved in 86%, menstrual dysfunction in 80%, acne in 81%, and hair loss in 33% of patients. The major side effects noted were irregular vaginal bleeding (16.1%), nausea (13.0%), and headaches (12.6%); only 36.6% of patients never complained of side effects. In this large study of consecutive patients presenting with clinically evident androgen excess, specific identifiable disorders (NCAH, CAH, HAIRAN syndrome, and androgen-secreting neoplasms) were observed in approximately 7% of subjects, whereas functional androgen excess, principally PCOS, was observed in the remainder. Hirsutism, menstrual dysfunction, or acne, but not alopecia, improved in the majority of patients treated with a combination suppressive therapy; although more than 60% experienced side effects.

Original languageEnglish (US)
Pages (from-to)453-462
Number of pages10
JournalJournal of Clinical Endocrinology and Metabolism
Volume89
Issue number2
DOIs
StatePublished - Feb 1 2004

Fingerprint

Androgens
Hirsutism
Steroid 21-Hydroxylase
Hyperplasia
Polycystic Ovary Syndrome
Alopecia
Acne Vulgaris
Insulin
Androgen Antagonists
Therapeutics
Symptom Assessment
Uterine Hemorrhage
Ovulation
Nausea
Population
Fertility
Headache
Neoplasms
Databases

ASJC Scopus subject areas

  • Endocrinology, Diabetes and Metabolism
  • Biochemistry
  • Endocrinology
  • Clinical Biochemistry
  • Biochemistry, medical

Cite this

Azziz, R., Sanchez, L. A., Knochenhauer, E. S., Moran, C., Lazenby, J., Stephens, K. C., ... Boots, L. R. (2004). Androgen Excess in Women: Experience with over 1000 Consecutive Patients. Journal of Clinical Endocrinology and Metabolism, 89(2), 453-462. https://doi.org/10.1210/jc.2003-031122

Androgen Excess in Women : Experience with over 1000 Consecutive Patients. / Azziz, Ricardo; Sanchez, L. A.; Knochenhauer, E. S.; Moran, C.; Lazenby, J.; Stephens, K. C.; Taylor, K.; Boots, L. R.

In: Journal of Clinical Endocrinology and Metabolism, Vol. 89, No. 2, 01.02.2004, p. 453-462.

Research output: Contribution to journalReview article

Azziz, R, Sanchez, LA, Knochenhauer, ES, Moran, C, Lazenby, J, Stephens, KC, Taylor, K & Boots, LR 2004, 'Androgen Excess in Women: Experience with over 1000 Consecutive Patients', Journal of Clinical Endocrinology and Metabolism, vol. 89, no. 2, pp. 453-462. https://doi.org/10.1210/jc.2003-031122
Azziz R, Sanchez LA, Knochenhauer ES, Moran C, Lazenby J, Stephens KC et al. Androgen Excess in Women: Experience with over 1000 Consecutive Patients. Journal of Clinical Endocrinology and Metabolism. 2004 Feb 1;89(2):453-462. https://doi.org/10.1210/jc.2003-031122
Azziz, Ricardo ; Sanchez, L. A. ; Knochenhauer, E. S. ; Moran, C. ; Lazenby, J. ; Stephens, K. C. ; Taylor, K. ; Boots, L. R. / Androgen Excess in Women : Experience with over 1000 Consecutive Patients. In: Journal of Clinical Endocrinology and Metabolism. 2004 ; Vol. 89, No. 2. pp. 453-462.
@article{9fc7f16d5b234e5d9086653636ed67ae,
title = "Androgen Excess in Women: Experience with over 1000 Consecutive Patients",
abstract = "The objective of the present study was to estimate the prevalence of the different pathological conditions causing clinically evident androgen excess and to document the degree of long-term success of suppressive and/or antiandrogen hormonal therapy in a large consecutive population of patients. All patients presenting for evaluation of symptoms potentially related to androgen excess between October 1987 and June 2002 were evaluated, and the data were maintained prospectively in a computerized database. For the assessment of therapeutic response, a retrospective review of the medical chart was performed, after the exclusion of those patients seeking fertility therapy only, or with inadequate follow-up or poor compliance. A total of 1281 consecutive patients were seen during the study period. Excluded from analysis were 408 patients in whom we were unable to evaluate hormonal status, determine ovulatory status, or find any evidence of androgen excess. In the remaining population of 873 patients, the unbiased prevalence of androgen-secreting neoplasms was 0.2{\%}, 21-hydroxylase-deficient classic adrenal hyperplasia (CAH) was 0.6{\%}, 21-hydroxylase-deficient nonclassic adrenal hyperplasia (NCAH) was 1.6{\%}, hyperandrogenic insulin-resistant acanthosis nigricans (HAIRAN) syndrome was 3.1{\%}, idiopathic hirsutism was 4.7{\%}, and polycystic ovary syndrome (PCOS) was 82.0{\%}. Fifty-nine (6.75{\%}) patients had elevated androgen levels and hirsutism but normal ovulation. A total of 257 patients were included in the assessment of the response to hormonal therapy. The mean duration of follow-up was 33.5 months (range, 6-155). Hirsutism improved in 86{\%}, menstrual dysfunction in 80{\%}, acne in 81{\%}, and hair loss in 33{\%} of patients. The major side effects noted were irregular vaginal bleeding (16.1{\%}), nausea (13.0{\%}), and headaches (12.6{\%}); only 36.6{\%} of patients never complained of side effects. In this large study of consecutive patients presenting with clinically evident androgen excess, specific identifiable disorders (NCAH, CAH, HAIRAN syndrome, and androgen-secreting neoplasms) were observed in approximately 7{\%} of subjects, whereas functional androgen excess, principally PCOS, was observed in the remainder. Hirsutism, menstrual dysfunction, or acne, but not alopecia, improved in the majority of patients treated with a combination suppressive therapy; although more than 60{\%} experienced side effects.",
author = "Ricardo Azziz and Sanchez, {L. A.} and Knochenhauer, {E. S.} and C. Moran and J. Lazenby and Stephens, {K. C.} and K. Taylor and Boots, {L. R.}",
year = "2004",
month = "2",
day = "1",
doi = "10.1210/jc.2003-031122",
language = "English (US)",
volume = "89",
pages = "453--462",
journal = "Journal of Clinical Endocrinology and Metabolism",
issn = "0021-972X",
publisher = "The Endocrine Society",
number = "2",

}

TY - JOUR

T1 - Androgen Excess in Women

T2 - Experience with over 1000 Consecutive Patients

AU - Azziz, Ricardo

AU - Sanchez, L. A.

AU - Knochenhauer, E. S.

AU - Moran, C.

AU - Lazenby, J.

AU - Stephens, K. C.

AU - Taylor, K.

AU - Boots, L. R.

PY - 2004/2/1

Y1 - 2004/2/1

N2 - The objective of the present study was to estimate the prevalence of the different pathological conditions causing clinically evident androgen excess and to document the degree of long-term success of suppressive and/or antiandrogen hormonal therapy in a large consecutive population of patients. All patients presenting for evaluation of symptoms potentially related to androgen excess between October 1987 and June 2002 were evaluated, and the data were maintained prospectively in a computerized database. For the assessment of therapeutic response, a retrospective review of the medical chart was performed, after the exclusion of those patients seeking fertility therapy only, or with inadequate follow-up or poor compliance. A total of 1281 consecutive patients were seen during the study period. Excluded from analysis were 408 patients in whom we were unable to evaluate hormonal status, determine ovulatory status, or find any evidence of androgen excess. In the remaining population of 873 patients, the unbiased prevalence of androgen-secreting neoplasms was 0.2%, 21-hydroxylase-deficient classic adrenal hyperplasia (CAH) was 0.6%, 21-hydroxylase-deficient nonclassic adrenal hyperplasia (NCAH) was 1.6%, hyperandrogenic insulin-resistant acanthosis nigricans (HAIRAN) syndrome was 3.1%, idiopathic hirsutism was 4.7%, and polycystic ovary syndrome (PCOS) was 82.0%. Fifty-nine (6.75%) patients had elevated androgen levels and hirsutism but normal ovulation. A total of 257 patients were included in the assessment of the response to hormonal therapy. The mean duration of follow-up was 33.5 months (range, 6-155). Hirsutism improved in 86%, menstrual dysfunction in 80%, acne in 81%, and hair loss in 33% of patients. The major side effects noted were irregular vaginal bleeding (16.1%), nausea (13.0%), and headaches (12.6%); only 36.6% of patients never complained of side effects. In this large study of consecutive patients presenting with clinically evident androgen excess, specific identifiable disorders (NCAH, CAH, HAIRAN syndrome, and androgen-secreting neoplasms) were observed in approximately 7% of subjects, whereas functional androgen excess, principally PCOS, was observed in the remainder. Hirsutism, menstrual dysfunction, or acne, but not alopecia, improved in the majority of patients treated with a combination suppressive therapy; although more than 60% experienced side effects.

AB - The objective of the present study was to estimate the prevalence of the different pathological conditions causing clinically evident androgen excess and to document the degree of long-term success of suppressive and/or antiandrogen hormonal therapy in a large consecutive population of patients. All patients presenting for evaluation of symptoms potentially related to androgen excess between October 1987 and June 2002 were evaluated, and the data were maintained prospectively in a computerized database. For the assessment of therapeutic response, a retrospective review of the medical chart was performed, after the exclusion of those patients seeking fertility therapy only, or with inadequate follow-up or poor compliance. A total of 1281 consecutive patients were seen during the study period. Excluded from analysis were 408 patients in whom we were unable to evaluate hormonal status, determine ovulatory status, or find any evidence of androgen excess. In the remaining population of 873 patients, the unbiased prevalence of androgen-secreting neoplasms was 0.2%, 21-hydroxylase-deficient classic adrenal hyperplasia (CAH) was 0.6%, 21-hydroxylase-deficient nonclassic adrenal hyperplasia (NCAH) was 1.6%, hyperandrogenic insulin-resistant acanthosis nigricans (HAIRAN) syndrome was 3.1%, idiopathic hirsutism was 4.7%, and polycystic ovary syndrome (PCOS) was 82.0%. Fifty-nine (6.75%) patients had elevated androgen levels and hirsutism but normal ovulation. A total of 257 patients were included in the assessment of the response to hormonal therapy. The mean duration of follow-up was 33.5 months (range, 6-155). Hirsutism improved in 86%, menstrual dysfunction in 80%, acne in 81%, and hair loss in 33% of patients. The major side effects noted were irregular vaginal bleeding (16.1%), nausea (13.0%), and headaches (12.6%); only 36.6% of patients never complained of side effects. In this large study of consecutive patients presenting with clinically evident androgen excess, specific identifiable disorders (NCAH, CAH, HAIRAN syndrome, and androgen-secreting neoplasms) were observed in approximately 7% of subjects, whereas functional androgen excess, principally PCOS, was observed in the remainder. Hirsutism, menstrual dysfunction, or acne, but not alopecia, improved in the majority of patients treated with a combination suppressive therapy; although more than 60% experienced side effects.

UR - http://www.scopus.com/inward/record.url?scp=1442303475&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=1442303475&partnerID=8YFLogxK

U2 - 10.1210/jc.2003-031122

DO - 10.1210/jc.2003-031122

M3 - Review article

VL - 89

SP - 453

EP - 462

JO - Journal of Clinical Endocrinology and Metabolism

JF - Journal of Clinical Endocrinology and Metabolism

SN - 0021-972X

IS - 2

ER -